<DOC>
	<DOCNO>NCT00002740</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation follow surgery and/or radiation therapy treat young patient newly diagnose advanced neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed Surgery and/or Radiation Therapy Treating Young Patients With Advanced Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose carboplatin give combination cyclophosphamide ( CTX ) etoposide follow high dose CTX , doxorubicin , vincristine patient newly diagnose stage IV neuroblastoma . II . Determine hematologic nonhematologic toxic effect regimen patient population . III . Determine change neuroblastoma tumor cell content peripheral blood stem cell ( PBSC ) collect follow chemotherapy . IV . Assess feasibility repetitive collection , storage , infusion PBSC multicycle high-dose chemotherapy pediatric patient . V. Assess hematopoietic recovery follow PBSC infusion well CD34 content CFU-GM yield PBSC product . VI . Assess response rate disease-free survival context phase I pilot study . VII . Determine feasibility administer twice-daily radiotherapy fraction post-chemotherapy residual tumor volume neuroblastoma patient . OUTLINE : This dose escalation study carboplatin . Patients receive induction chemotherapy consist vincristine IV 24 hour , cyclophosphamide IV 4 hour , doxorubicin IV 24 hour day 0 , 1 , 21 , 22 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SQ ) IV begin day 3 24 continue blood count recover . Patients undergo peripheral blood stem cell ( PBSC ) collection course 2 induction chemotherapy . Patients receive G-CSF SQ IV 2 day prior collection . PBSC collect daily 1-3 day . Patients may undergo autologous bone marrow collection course 1 consolidation therapy ( PBSC collection ) . Following mobilization , patient receive consolidation chemotherapy consist etoposide IV 4 hour day 0 , 1 , 2 carboplatin IV 1 hour cyclophosphamide IV 4 hour day 0 1 . Patients receive G-CSF SQ IV begin day 3 ( within 4 hour PBSC infusion ) continue blood count recover . Patients receive PBSC reinfusion 48-72 hour follow completion chemotherapy course . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Upon recovery consolidation chemotherapy , patient disease progression undergo tumor resection without radiotherapy . Patients undergo radiotherapy receive therapy twice daily 7 day . Patients disease progression , le 2 % detectable bone marrow disease , adequate bone marrow cellularity may undergo additional therapy consist autologous bone marrow transplantation per appropriate transplant protocol . Cohorts 6-12 patient receive escalate dos carboplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 4 12 patient experience dose limit toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 24-30 patient accrue study within approximately 2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose stage IV neuroblastoma one following : Histologic verification Demonstration tumor cell clump bone marrow elevate urinary catecholamine metabolites Initial presentation lowstage disease allow followed progression stage IV disease PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Not specify Hematopoietic : ( unless bone marrow involvement tumor ) Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 3.0 mg/dL Renal : Creatinine le 1.5 mg/dL Creatinine clearance radionuclide GFR great 60 mL/min Cardiovascular : EKG normal Ejection fraction least 55 % radionuclide MUGA OR Fractional shorten least 28 % echocardiogram Other : No significant organ dysfunction precludes study treatment Body weight least 10 kg Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy No prior radiotherapy except emergency treatment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>